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Abstract: Within this work we describe the synthesis of versatile substituted 2-phenyl benzothiazole 3–10 and 2-phenylbenzimidazole 12–19 
derivatives bearing amidino groups. Furthermore, the synthesized compounds were explored for their antiproliferative activity in vitro on three 
cancer cell lines. Tested compounds showed moderate to strong antiproliferative activity.  Furthermore, the type of the attached amidino 
group on benzazole nuclei has the significant impact on the antiproliferative activity only within benzimidazole derivatives with 2-imidazolinyl 
substituted derivatives being more active in comparison to amidino substituted analogues. All obtained results revealed that this type of 
benzothiazole derivatives have a great potential for further optimization and development of more efficient potential antiproliferative agents. 
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INTRODUCTION 
UE to their biological importance based on a broad 
spectrum of biological features, benzimidazole and 
benzothiazole derivatives are nowadays important and 
well-known privileged building structural motifs in medici-
nal and pharmaceutical chemistry.[1,2] These nitrogen and 
sulphur-containing heterocycles become unavoidable sub-
structures in the rational design of novel drugs.[3,4] These 
derivatives has been proven to possess important role in 
the structure of various biologically important natural and 
synthetic molecules, while among their versatile pharma-
cological features, the most important ones are 
antimicrobial,[5,6] antitumor,[7,8] antiviral,[9] anti-inflam-
manory,[10] antihistaminic,[11] antioxidant,[12,13] etc. Imp-
ortantly, since benzimidazoles are bioisosteres of purines, 
which offer the possibility of interactions with bio-
molecules from the living systems, benzimidazole 
derivatives play a crucial role in the function of many 
biologically important molecules like DNA, RNA or 
different proteins included in numerous metabolic 
processes in living organisms.[14,15]   
 Recently, we have published several papers which 
describe the antiproliferative activity and potential of ver-
satile benzothiazole and benzimidazole derivatives substi-
tuted with carboxamido, amino, halogeno, cyano, amidino, 
amino or nitro groups placed at different positions on the 
mentioned scaffold. The most significant biological im-
portance was observed with amidino substituted ben-
zazoles bearing different types of amidine substituents 
suchlike unsubstituted, isopropyl, morpholinyl or imidazoli-
nyl.[16] Obtained results revealed that the most significant 
influence and the enhancement of the antiproliferative ac-
tivity in vitro showed benzazole derivatives substituted 
with cyclic amidino substituent, namely 2-imidazolinyl 
group with IC50 values in submicromolar range of concen-
trations (Fig. 1).[17,18] Interestingly, some of the tested de-
rivatives showed selectivity towards cancer cells as well as 
very low cytotoxicity against normal fibroblasts. 
 Additionally, we have also explored the interaction 
with DNA/RNA of chosen amidino substituted benzo-
thiazoles/benzimidazoles in order to define one of the 
possible mechanisms of biological action of most active 
derivatives. The results clearly indicated that amidino 
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substituents which are usually placed at the termini of the 
molecules have great importance in the interaction with 
biological targets causing enhanced antitumor activity and 
stronger interaction with biomacromolecules.[19–21]  
 Amidines seem to contribute significantly to the 
molecule/possible biological target complex stability 
through H-bonding and electrostatic interactions.[22,23] 
Thus, in several publications we have proved that by 
incorporation of positively charged amidine moiety at the 
end of the heteroaromatic molecules, we could 
significantly improve the biological activity and orient the 
function of the molecule toward the binding to an 
electronegatively charged molecule such as DNA/RNA.[24] 
Studied benzothiazole derivatives bearing amidine moiety 
intercalate into ds-RNA by binding into minor groove of AT-
DNA, and agglomerate along GC-DNA (Fig. 2). Furthermore, 
benzothiazoles also interact with ss-RNA, but only 2-
imidazolinyl 2-phenylbenzothiazole displayed well defined 
orientation and dominant binding mode (by induced CD 
signals) with poly A and poly G.[25] Amidino substituted 
benzimidazole-2-carboxamide as groove binder evidenced 
sequence-selective binding in the A-T rich side (Fig. 2).[26] 
 As a continuation of our scientific research based on 
the synthesis of biologically active benzazoles, all the 
above-mentioned facts prompted us to design and 
synthesize novel amidino substituted benzothiazole / 
enzimidazole derivatives in order to evaluate their 
antiproliferative activity in vitro. The obtained results are 
discussed in terms of SAR to define the influence of the type 
of amidino group and heteroatom placed in the 
heterocyclic nuclei as well as the type of substituent on the 
phenyl ring on the antiproliferative activity.  
EXPERIMENTAL 
Chemistry 
GENERAL METHODS  
All chemicals and solvents were purchased from 
commercial suppliers including Aldrich, Fluka and Acros. 
Melting points were recorded on an Original Kofler 
Mikroheitztisch apparatus (Reichert, Wien) and SMP11 
Bibby apparatus and are not corrected. All NMR spectra 
were measured in DMSO-d6 solutions using TMS as an 
internal standard. The 1H NMR and the 13C NMR spectra 
were recorded with the Bruker Avance DPX-300, Bruker AV-
600 or Bruker Avance III HD 400. Chemical shifts are 
reported in parts per million (ppm) relative to TMS. LC-MS 
was performed on the Waters Acquity UHPLC system. 
Synthesis 
Synthesis of main precursors for the synthesis of targeted 
benzothiazoles and benzimidazoles, namely 2-amino-5-
amidiniumbenzenethiolate 2a[27] and 2-amino-(4,5-
dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 
2b[27] and 4-amidinium-1,2-phenylenediamine chloride 11a 
and 2-(3,4-diaminophenyl)-4,5-dihydro-1H-imidazol-3-ium 
chloride 11b was carried out according to the previously 
published experimental procedures.[28] 
 
GENERAL METHOD FOR THE SYNTHESIS OF 
BENZOTHIAZOLE DERIVATIVES 3–10 
A mixture of the corresponding aldehyde 1a–1d (0.5 mmol) 
and 2-amino-5-amidiniumbenzenethiolate 2a (0.5 mmol) 
or 2 – amino – 5 - (4,5 – dihydro - 1H – imidazol – 3 – ium - 2 - yl)ben-
zenethiolate hydrate 2b (0.5 mmol) in glacial acetic acid (5 
mL) was stirred at reflux under nitrogen for 3 h, followed by 
the addition of concentrated hydrochloric acid (0.5 mL) and 
additionally stirred at room temperature for 1 h. After 
addition of diethyl ether, the crude product was filtered off, 
washed with diethyl ether and crystallized from 0.1 M 
hydrochloric acid/acetone mixture to obtain pure 
compounds 3–10. 
 
6-Amidinium-2-(4-cyanophenyl)benzothiazole Chloride 3  
Using above described method from 4-cyanobenz-
aldehyde 1a (0.066 g, 0.5 mmol) and 2-amino-5-amid-
iniumben-zenethiolate 2a (0.084 g, 0.5 mmol) was 
obtained 0.088 g (52 %) of pale yellow solid; mp = 291–
295 °C; 1H NMR (400 MHz, DMSO-d6) δ / ppm: 9.64 (bs, 
2H, -C(NH2)2+), 9.45 (bs, 2H, -C(NH2)2+), 8.79 (s, 1H, Ar-H), 
8.33 (m, 3H, Ar-H), 8.08 (d, 2H, J = 7.2 Hz, Ar-H), 8.00 (d, 
1H, J = 7.7 Hz, Ar-H); 13C NMR (100 MHz, DMSO-d6) 
δ/ppm: 169.5, 165.4, 156.2, 136.0, 135.1, 133.4 (2C), 
128.2 (2C), 126.6, 125.5, 123.7, 123.5, 118.2, 114.1; LC-
MS (ESI) m / z: 279.2 [(M–Cl–)+]. 
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Figure 1. Previously published amidino substituted benzo-
thiazole and benzimidazole derivatives with antiprolife-
rative activity. 
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Figure 2. Previously published amidino substituted benzo-
thiazole and benzimidazole derivatives with antiprolife-
rative activity and interaction with DNA/RNA. 
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6-Amidinium-2-(4-chlorophenyl)benzothiazole chloride 4 
Using above described method from 4-chlorobenzaldehyde 
1b (0.075 g, 0.5 mmol) and 2-amino-5-amidiniumben-
zenethiolate 2a (0.084 g, 0.5 mmol) was obtained 0.091 g  
(56 %) of colorless solid; mp = 299-302 °C; 1H NMR (600 MHz, 
DMSO-d6) δ / ppm: 9.41 (bs, 4H, -C(NH2)2+), 8.72 (s, 1H, Ar-H), 
8.27 (d, 1H, J = 7.2 Hz, Ar-H), 8.18 (d, 2H, J = 6.5 Hz, Ar-H), 
7.95 (d, 1H, J = 7.1 Hz, Ar-H), 7.69 (d, 2H, J = 6.8 Hz, Ar-H); 13C 
NMR (100 MHz, DMSO-d6) δ / ppm: 170.2, 165.4, 156.4, 
138.9, 134.8, 131.1, 129.6 (2C), 129.3 (2C), 126.5, 125.1, 
123.5, 123.1; LC-MS (ESI) m / z: 288.1 [(M–Cl–)+]. 
 
6-Amidinium-2-(4-trifluoromethylphenyl)benzothiazole 
chloride 5  
Using above described method from 4-trifluormethyl-
benzaldehide 1c (0.087 g, 0.5 mmol) and 2-amino-5-
amidiniumbenzenethiolate 2a (0.084 g, 0.5 mmol) was 
obtained 0.074 g (41 %) of colorless solid; mp = 287–291 °C; 
1H NMR (400 MHz, DMSO-d6) δ / ppm: 9.52 (bs, 4H, -
C(NH2)2+), 8.78 (s, 1H, Ar-H), 8.38 (d, 2H, J = 7.3 Hz, Ar-H), 
8.33 (d, 1H, J = 8.3 Hz, Ar-H), 7.99 (m, 3H, Ar-H); 13C NMR 
(100 MHz, DMSO-d6) δ / ppm: 169.7, 165.4, 156.3, 135.8, 
134.9, 131.6 (2JCF = 31.9 Hz), 128.4 (2C), 126.6, 126.5 (2C, 
3JCF = 3.2 Hz), 125.5, 123.8 (2C, 1JCF = 270.9 Hz), 123.7, 123.4; 
LC-MS (ESI) m / z: 322.2 [(M–Cl–)+]. 
 
6-Amidinium-2-(2,4-dihydroxyphenyl)benzothiazole 
chloride 6[13]  
Using above described method from 2,4-dihydroxybenz-
aldehyde 1d (0.069 g, 0.5 mmol) and 2-amino-5-
amidiniumbenzenethiolate 2a (0.084 g, 0.5 mmol) was 
obtained 0.083 g (52 %) of pale yellow solid; mp > 300 °C. 
1H NMR (300 MHz, DMSO-d6) δ / ppm: 11.57 (s, 1H, -OH), 
10.34 (s, 1H, -OH), 9.42 (bs, 2H, -C(NH2)2+), 9.14 (bs, 2H, -
C(NH2)2+), 8.59 (s, 1H, Ar-H), 8.14–8.10 (m, 2H, Ar-H), 7.88 
(d, 1H, J = 8.6 Hz, Ar-H), 6.57 (s, 1H, Ar-H), 6.49 (d, 1H, J = 
8.7 Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 168.9, 
165.5, 162.3, 158.5, 154.9, 134.3, 130.1, 125.7, 123.1, 
122.5, 121.2, 110.4, 108.6, 102.6; LC- MS (ESI) m / z: 286.1 
[(M-Cl–)+]. 
 
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(4-
cyanophenyl)benzothiazole chloride 7  
Using above described method from 4-cyanobenzaldehyde 
1a (0.066 g, 0.5 mmol) and 2-amino-5-(4,5-dihydro-1H-
imidazol-3-ium-2-yl)benzenethiolate hydrate 2b (0.106 g, 
0.5 mmol) was obtained 0.071 g (42 %) of pale yellow solid; 
mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ / ppm: 10.89 
(s, 2H, -C(NH-)2+), 8.94 (s, 1H, Ar-H), 8.37 (d, 1H, J = 8.6 Hz, 
Ar-H), 8.34 (d, 2H, J = 8.3 Hz, Ar-H), 8.16 (d, 1H, J = 8.6 Hz, 
Ar-H), 8.09 (d, 2H, J = 8.3 Hz, Ar-H), 4.06 (s, 4H, -CH2CH2-); 
13C NMR (75 MHz, DMSO-d6) δ / ppm: 170.1, 164.6, 156.6, 
135.9, 135.4, 133.5 (2C), 128.3 (2C), 126.8, 124.1, 123.9, 
119.6, 118.2, 114.2, 44.5 (2C); LC- MS (ESI) m / z: 305.5  
[(M-Cl–)+]. 
 
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(4-
chlorophenyl)benzothiazole chloride 8  
Using above described method from 4-chlorobenzaldehyde 
1b (0.075 g, 0.5 mmol) and 2-amino-5-(4,5-dihydro-1H-
imidazol-3-ium-2-yl)benzenethiolate hydrate 2b (0.106 g, 
0.5 mmol) was obtained 0.071 g (42 %) of colorless solid; 
mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ / ppm: 10.81 
(s, 2H, -C(NH-)2+), 8.88 (s, 1H, Ar-H), 8.32 (d, 1H, J = 8.6 Hz, 
Ar-H), 8.19 (d, 2H, J = 8.3 Hz, Ar-H), 8.12 (d, 1H, J = 8.4 Hz, 
Ar-H), 7.70 (d, 2H, J = 8.3 Hz, Ar-H), 4.06 (s, 4H, -CH2CH2-); 
13C NMR (75 MHz, DMSO-d6) δ / ppm: 170.8, 164.7, 156.8, 
137.1, 135.1, 131.0, 129.7 (2C), 129.4 (2C), 126.7, 123.8, 
123.5, 119.2, 44.5 (2C); LC- MS (ESI) m / z: 314.2 [(M-Cl–)+]. 
 
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(4-
trifluoromethylphenyl)benzothiazole chloride 9  
Using above described method from 4-trifluormethyl-
benzaldehide 1c (0.087 g, 0.5 mmol) and 2-amino-5-(4,5-
dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 
2b (0.106 g, 0.5 mmol) was obtained 0.098 g (51 %) of 
colorless solid; mp = 264-267 °C. 1H NMR (600 MHz, DMSO-
d6) δ / ppm: 10.86 (s, 2H, -C(NH-)2+), 8.93 (s, 1H, Ar-H), 8.38 
(m, 3H, Ar-H), 8.15 (d, 1H, J = 7.9 Hz, Ar-H), 7.99 (d, 2H, J = 
7.4 Hz, Ar-H), 4.06 (s, 4H, -CH2CH2-); 13C NMR (100 MHz, 
DMSO-d6) δ / ppm: 170.2, 164.3, 156.5, 135.6, 135.1, 131.7 
(2JCF = 32.0 Hz), 128.4 (2C), 126.9, 126.4 (2C, 3JCF = 3.0 Hz), 
124.1, 123.8 (2C, 1JCF = 270.8 Hz), 123.7, 119.4, 44.5 (2C); 
LC-MS (ESI) m / z: 348.2 [(M–Cl–)+]. 
 
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(2,4-
dihydroxyphenyl)benzothiazole chloride 10[13]  
Using above described method from 2,4-dihydroxybenz-
aldehyde 1d (0.069 g, 0.5 mmol) and 2-amino-5-(4,5-
dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 
2b (0.106 g, 0.5 mmol) was obtained 0.101 g (58 %) of pale 
yellow solid; mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ / 
ppm: 11.58 (s, 1H, -OH), 10.69 (s, 2H, -C(NH-)2+), 10.36 (s, 
1H, -OH), 8.76 (d, 1H, J = 1.7 Hz, Ar-H), 8.16-8.13 (m, 2H, Ar-
H), 8.04 (dd, 1H, J = 8.6 Hz, J = 1.9 Hz, Ar-H), 6.58 (d, 1H, J = 
2.3 Hz, Ar-H), 6.49 (dd, 1H, J = 8.8 Hz, J = 2.3 Hz, Ar-H), 4.04 
(s, 4H, -CH2CH2-); 13C NMR (151 MHz, DMSO-d6) δ / ppm: 
169.0, 164.6, 162.4, 158.6, 155.3, 134.7, 130.2, 126.1, 
123.1, 121.6, 117.1, 110.6, 108.7, 102.6, 44.3 (2C); LC-MS 
(ESI) m / z: 312.1 [(M–Cl)+]. 
 
GENERAL METHOD FOR THE SYNTHESIS OF 
BENZIMIDAZOLE DERIVATIVES 12–19 
A mixture of equimolar amounts of the corresponding 
aldehyde 1a–1d and 4-amidinium-1,2-phenylenediamine 
11a or 2-(3,4-diaminophenyl)-4,5-dihydro-1H-imidazol-3-ium 
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chloride 11b in absolute ethanol with p-benzoquinone 
was stirred at reflux for 4 hours. The crude product  
was then filtered off, washed with diethyl ether and 
recrystallized from ethanol to obtain pure compounds 
12–19.[17] 
 
5(6)-Amidinium-2-(4-cyanophenyl) 
benzimidazole chloride 12 
Using above described method from 4-cyanobenzaldehyde 
1a (0.075 g, 0.6 mmol), 4-amidinium-1,2-phenylene-
diamine 11a (0.107 g, 0.6 mmol) and p-benzoquinone 
(0.062 g, 0.6 mmol) in absolute ethanol (5 mL) was obtained 
0.148 g (87 %) of grey solid; mp > 300 °C; 1H NMR (300 MHz, 
DMSO-d6) δ/ppm: 14.15 (bs, 1H, Bim-NH), 9.39 (s, 2H, -
C(NH2)2+), 9.11 (s, 2H, -C(NH2)2+), 8.46 (d, 2H, J =8.4 Hz, Ar-H), 
8.07 (d, 2H, J =8.8 Hz, Ar-H), 8.30 (s, 1H, Ar-H), 7.83–7.67 (m, 
2H, Ar-H); 13C NMR (75 MHz, DMSO-d6) δ/ppm: 166.7, 166.4, 
150.5, 133.9, 133.6 (2C), 129.8, 128.1 (2C), 123.4, 121.7, 
120.5, 119.0, 113.3; LC-MS (ESI) m / z: 262.5 [(M–Cl-)+]. 
 
5(6)-Amidinium-2-(4-chlorophenyl) 
benzimidazole chloride 13 
Using above described method from 4-chlorobenzaldehyde 
1b (0.075g, 0.5 mmol), 4-amidinium-1,2-phenylenediamine 
11a (0.099 g, 0.5 mmol) and p-benzoquinone (0.057 g,  
0.5 mmol) in absolute ethanol (5 mL) was obtained 0.118 g 
(72 %) of violet solid; mp 256-258 °C; 1H NMR (300 MHz, 
DMSO-d6) δ/ppm: 13.84 (bs, 1H, Bim-NH), 9.37 (bs, 2H, -
C(NH2)2+), 9.07 (bs, 2H, -C(NH2)2+), 8.30 (d, 2H, J = 8.8 Hz, Ar-
H), 8.19 (s, 1H, Ar-H), 7.80 (d, 1H, J = 7.6 Hz, Ar-H), 7.70 (d, 
1H, J = 8.0 Hz, Ar-H), 7.68 (d, 2H, J = 8.8 Hz, Ar-H); 13C NMR 
(75 MHz, DMSO-d6) δ / ppm: 166.5, 166.4, 165.8, 153.7, 
135.7, 129.7 (2C), 129.6, 129.2 (2C), 128.5, 122.7, 122.5, 
121.9; LC-MS (ESI) m / z: 271.5 [(M-Cl-)+]. 
 
5(6)-Amidinium-2-(4-trifluoromethylphenyl)-
benzimidazole chloride 14 
Using above described method from 4-trifluormethyl-
benzaldehide 1c (0.075 g, 0.4 mmol), 4-amidinium-1,2-
phenylenediamine 11a (0.080 g, 0.4 mmol) and p-benzo-
quinone (0.046 g, 0.4 mmol) in absolute ethanol (5 mL) was 
obtained 0.098 g (67 %) of dark grey solid; mp 252-254 °C; 
1H NMR (600 MHz, DMSO-d6) δ / ppm: 14.02 (s, 1H, Bim-
NH), 9.40 (s, 2H, -C(NH2)2+), 9.13 (s, 2H, -C(NH2)2+), 8.51 (d, 
2H, J = 8.4 Hz, Ar-H), 8.23 (s, 1H, Ar-H), 7.98 (d, 2H, J = 8.4 
Hz, Ar-H), 7.83 (bs, 1H, Ar-H), 7.73 (d, 1H, J = 8.0 Hz, Ar-H); 13C 
NMR (75 MHz, DMSO-d6) δ / ppm: 166.5, 165.8, 153.0, 133.6, 
130.7 (q), 128.2 (2C), 126.5 (2C), 125.9, 123.1, , 122.4, 120.5, 
114.7, 113.3; LC-MS (ESI) m / z: 305.5 [(M-Cl-)+]. 
 
5(6)-Amidinium-2-(2,4-dihydroxyphenyl)- 
benzimidazole chloride 15[13] 
Using above described method from 2,4-dihydroxybenz-
aldehyde 1d (0.100g, 0.7 mmol), 4-amidinium-1,2-phenyl-
enediamine 11a (0.135 g, 0.7 mmol) and p-benzoquinone 
(0.078 g, 0.7 mmol) in absolute ethanol (3.5 mL) was 
obtained 0.023 g (10.4 %) of violet solid; mp > 300 °C; 1H 
NMR (300 MHz, DMSO-d6) δ / ppm: 13.46 (bs, 1H, -OH), 
12.73 (bs, 1H, Bim-NH), 10.16 (bs, 1H, -OH), 9.30 (bs, 2H, -
C(NH2)2+), 8.99 (bs, 2H, -C(NH2)2+), 8.12 (bs, 1H, Ar-H), 7.99 (d, 
1H, J = 8.5 Hz, Ar-H), 7.77 (d, 1H, J = 7.7 Hz, Ar-H), 7.68 (d, 1H, 
J = 8.6 Hz, Ar-H), 6.49 (dd, 1H, J = 8.5 Hz, J = 2.2 Hz, Ar-H), 6.45 
(d, 1H, J = 2.1 Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 
166.0, 165.9, 161.7, 161.5, 160.1, 159.9, 155.5, 154.8, 145.0, 
140.8, 137.2, 133.0, 128.6, 128.4, 122.3, 122.0, 121.4, 121.3, 
117.8, 117.5, 111.7, 111.6, 108.0 (2C), 104.1, 104.0, 103.0 
(2C); LC-MS (ESI) m / z: 269.1 [(M-Cl-)+]. 
 
5(6)-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(4-
cyanophenyl)benzimidazole chloride 16  
Using above described method from 4-cyanobenzaldehyde 
1a (0.075 g, 0.6 mmol), 2-(3,4-diaminophenyl)-4,5-dihydro-
1H-imidazol-3-ium chloride 11b (0.121 g, 0.6 mmol) and  
p-benzoquinone (0.062 g, 0.6 mmol) in absolute ethanol  
(4 mL) was obtained 0.112 g (72 %) of grey solid; mp 235-
237 °C; 1H NMR (300 MHz, DMSO-d6) δ / ppm: 14.13 (bs, 
1H, Bim-NH), 10.64 (s, 2H, -C(NH-)2+), 8.43 (d, 2H, J = 8.4 Hz, 
Ar-H), 8.19 (d, 1H, J = 8.4 Hz, Ar-H), 8.05 (d, 2H, J = 8.5 Hz, 
Ar-H), 7.98 (d, 1H, J = 8.3 Hz, Ar-H), 7.86 (s, 1H, Ar-H), 4.01 
(s, 4H, -CH2CH2-); 13C NMR (150 MHz, DMSO-d6) δ / ppm: 
165.3, 164.4, 150.3, 142.2, 134.1, 133.3, 133.0 (2C), 132.7, 
129.4, 127.6, 118.4, 115.6, 113.2, 112.8. LC-MS (ESI) m / z: 
288.6 [(M-Cl-)+]. 
 
5(6)-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(4-
chlorophenyl)benzimidazole chloride 17 
Using above described method from 4-chlorobenzaldehyde 
1b (0.075 g, 0.5 mmol), 2-(3,4-diaminophenyl)-4,5-dihydro-
1H-imidazol-3-ium chloride 11b (0.113 g, 0.5 mmol) and  
p-benzoquinone (0.057 g, 0.5 mmol) in absolute ethanol  
(4 mL) was obtained 0.124 g (70 %) of violet solid; mp 260–
262 °C; 1H NMR (600 MHz, DMSO-d6) δ / ppm: 14.02 (s, 1H, 
Bim-NH), 10.68 (bs, 2H, -C(NH-)2+), 8.41 (s, 1H, Ar-H), 8.30 (d, 
2H, J = 7.6 Hz, Ar-H), 7.88 (bs, 1H, Ar-H), 7.81 (d, 1H, J = 7.8 
Hz, Ar-H), 7.70 (d, 2H, J = 8.6 Hz, Ar-H), 4.03 (s, 4H, -CH2CH2); 
13C NMR (75 MHz, DMSO-d6) δ / ppm: 165.9, 165.7, 150.1, 
135.9, 129.7, 129.6 (2C), 129.2 (2C), 128.6, 123.4, 116.1, 
115.9, 45.0 (2C); LC-MS (ESI) m / z: 298.2 [(M-Cl-)+]. 
 
5(6)-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(4-
trifluoromethylphenyl)benzimidazole chloride 18 
Using above described method from 4-trifluoromethyl-
benzaldehide 1c (0.075 g, 0.4 mmol), 2-(3,4-diamino-
phenyl)-4,5-dihydro-1H-imidazol-3-ium chloride 11b (0.091 
g, 0.4 mmol) and p-benzoquinone (0.046 g, 0.4 mmol) in 
absolute ethanol (4 mL) was obtained 0.097 g (61 %) of dark 
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grey solid; mp 281-283 °C; 1H NMR (600 MHz, DMSO-d6)  
δ / ppm: 14.20 (bs, 1H, Bim-NH), 10.74 (bs, 2H, -C(NH-)2+), 
8.51 (d, 2H, J = 8.4 Hz, Ar-H), 8.42 (s, 1H, Ar-H), 7.97 (d, 2H, 
J = 8.5 Hz, Ar-H), 7.94-7.82 (m, 2H, Ar-H), 4.02 (s, 4H, -
CH2CH2-); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 165.9, 
165.5, 147.9, 133.7, 132.5, 130.7 (q), 128.4 (2C), 126.6 (2C), 
125.8, 123.2, 116.1, 113.2, 44.9 (2C); LC-MS (ESI) m / z: 
331.6 [(M-Cl-)+]. 
 
5(6)-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(2,4-
dihydroxyphenyl)benzimidazole chloride 19[13] 
Using above described method from 2,4-dihydroxy-
benzaldehyde 1d (0.080 g, 0.6 mmol), 2-(3,4-diamino-
phenyl)-4,5-dihydro-1H-imidazol-3-ium chloride 11b (0.123 
g, 0.6 mmol) and p-benzoquinone (0.063 g, 0.6 mmol) in 
absolute ethanol (3.5 mL) was obtained 0.035 g (18.2 %) of 
grey-violet solid; mp > 300 °C; 1H NMR (600 MHz, DMSO-d6) 
δ / ppm: 13.70 (bs, 1H, -OH), 13.58 (bs, 1H, -OH), 12.75 (s, 
1H, Bim-NH), 12.58 (s, 1H, Bim-NH), 10.56 (bs, 4H, -C(NH-
)2+), 10.23 (s, 1H, -OH), 10.21 (s, 1H, -OH), 8.35 (s, 1H, Ar-H), 
8.24 (s, 1H, Ar-H), 8.06 (d, 1H, J = 8.3 Hz, Ar-H), 7.99 (d, 1H, J 
= 7.1 Hz, Ar-H), 7.85–7.82 (m, 3H, Ar-H), 7.77 (d, 1H, J = 7.2 
Hz, Ar-H), 6.49 (d, 2H, J = 8.6 Hz, Ar-H), 6.45 (s, 2H, Ar-H), 4.02 
(s, 8H, -CH2CH2-); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 
165.8, 162.2, 160.4, 129.1, 123.1, 115.9, 108.5 (2C), 104.5, 
103.5 (2C), 44.7 (2C); LC-MS (ESI) m / z: 298.2 [(M-Cl-)+]. 
Antiproliferative Activity 
The experiments were carried out on three human cell 
lines: HCT 116 (colon carcinoma), H 460 (lung carcinoma) 
and MCF-7 (breast carcinoma) according to the previously 
published experimental procedure.[15,17]  
 Briefly, the cells were grown in DMEM medium with 
the addition of 10 % fetal bovine serum (FBS), 2 mM L-
glutamine, 100 U mL–1 penicillin and 100 µg mL–1 
streptomycin, and cultured as monolayers at 37 °C in a 
humidified atmosphere with 5 % CO2. Cells were seeded at 
2×103 cells/well in a standard 96-well microtiter plates and 
left to attach for 24 h. Next day, test compound was added 
in five serial 10-fold dilutions. The cell growth rate was 
evaluated after 72 h of incubation, using MTT assay. 
Obtained results are expressed as IC50 value which stands 
for the concentration of the compound necessary for 50 % 
of growth inhibition. The IC50 values are calculated from 
concentration-response curve using linear regression 
analysis by fitting the test concentrations that give PG 
values above and below the reference value (i.e. 50 %). 
Each test was performed in quadruplicate in at least two 
individual experiments. 
 
RESULTS AND DISCUSSION 
Chemistry 
The targeted amidino substituted benzothiazoles 3–10 
were synthesized according to the procedure shown in 
Scheme 1 by using conventional methods for construction 
of structurally related fused heteroaromatic derivatives. 
Starting from commercially available substituted benzalde-
hydes 1a–1d and amidino substituted benzenethiolates 
2a–2b, cyclocondensation in refluxing acetic acid followed 
by quenching with hydrochloric acid, afforded benzothia-
zoles 3–10 as hydrochloride salts in moderate to good re-
action yields. This method has been found to be efficient 
for direct condensation of thermally and acid stable alde-
hydes whith amidino substituted 2–aminothiophenoles 
without using any catalyst or oxidant. The precursors 2a–
2b as zwitterions were prepared by Pinner reaction from 6-
cyanobenzothiazole according to our previously described 
and optimized method.[27] 
 Amidino substituted benzimidazole derivatives 12–
19 were prepared following the experimental protocol as 
shown in the Scheme 2. Within the reaction of cyclocon-
densation, from substituted benzaldehydes 1a–1d and 4-
amidino/4-(2-imidazolinyl)-1,2-phenylene-diamines hydro-
chlorides 11a–11b, corresponding 2-phenyl substituted 
benzimidazoles 12–19 as hydrochloride salts were pre-
pared in moderate reaction yields. Amidines 11a–11b 
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Scheme 1. Synthesis of amidino substituted benzothiazole derivatives 3–10. 
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obtained in the acidic Pinner reaction from corresponding 
cyano substituted precursors according to the previously 
published procedures.[17]  
 The structures of all newly prepared benzothiazole 
and benzimidazole derivatives were determined by using 
1H and 13C NMR spectroscopy and mass spectrometry. NMR 
analysis based on the values of H-H coupling constants and 
chemical shifts in the 1H spectra confirmed the structures 
of compounds. Furthermore, 13C NMR chemical shifts were 
consistent with the suggested structures.  
 The appearance of protons related to unsubstituted 
and cyclic amidino substituent in the aliphatic part can be 
observed in 1H for unsubstituted and both in 1H and 13C 
NMR for 2-imidazolinyl amidine. IR spectroscopy was used 
for the monitoring of Pinner reaction due to the synthesis 
of main precursors 2a, 2b, 11a and 11b. 
Antiproliferative Activity 
In order to assess their antiproliferative activity in vitro, all 
prepared benzothiazole and benzimidazole derivatives 
were tested against HCT116 (colon carcinoma), H460 (lung 
carcinoma) and MCF-7 (breast carcinoma) cancer cell lines. 
For comparison reasons, a reference compound, etoposide 
was used (Table 1).  
 The synthesized compounds were designed in order 
to study the influence of the heteroatom in benzazole 
nuclei, the type of substituent placed on the phenyl ring 
and the type of the amidino group attached on the 
benzazole nuclei on antiproliferative activity in vitro and 
selectivity towards three cancer cells. Obtained results 
revealed that the type of benzazole nuclei significantly 
influenced the antiproliferative effect on tested cells, thus 
confirming the influence of the heteroatom on the 
antiproiliferative activity (Fig. 3). In general, most of the 
tested compounds showed moderate antiproliferative 
effect, while benzothiazole derivatives 3–10 displayed 
significantly better activity in comparison to their 
benzimidazole analogues 12–19. Among all tested 
benzothiazole amidines, there was no notable difference in 
the antiproliferative activity between amidino substituted 
3–6 and 2-imidazolinyl substituted 7–10 derivatives with 
the exception of 2,4-dihydroxy substituted derivatives 6 
and 10. Amidino substituted benzothiazole 6 did not show 
any activity while its 2-imidazolinyl analogue 10 showed 
moderate antiproliferative effect with selective activity 
toward H 460 cancer cell. On the other hand, all tested 
benzimidazole derivatives showed lower antiproliferative 
activity in comparison to their benzothiazole analogues.  
 Unlike benzothiazole amidines 3–10, the 
antiproliferative activity of benzimidazole amidines 12–19, 
in general was influenced by the type of attached amidino 
group. 2-Imidazolinyl substituted derivatives 16–18 
showed a slightly improvement of antiproliferative effect in 
comparison to their amidino substituted analogues 12–14 
with some selectivity against MCF-7 cells, especially for 
derivatives 17 and 18.  
 Surprisingly, the activity of derivatives 15 and 19, 
substituted with two hydroxy groups was not influenced by 
the type of the amidino group.  
 In conclusion, taking into account the obtained 
results, it could be concluded that benzazole scaffold, 
especially benzothiazole nuclei, offer a great potential for 
further optimization of the structure which could lead to 
more active and selective benzothiazole derivatives as a 
promising antiproliferative agents.  
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Scheme 2. Synthesis of amidino substituted benzimidazole derivatives 12–19. 
 
Am
R1
N
X
2-imidazolinyl substituted 
benzimidazoles showed improvement 
of antiproliferative activity
R2
X = S 
X = NH
benzothiazole derivatives showed 
strong antiproliferative activity
R1
 = H, OH
R2
 = CN, Cl, CF3,
 OH  
Figure 3. Insights into SAR for antiproliferative activity in 
vitro of benzazole derivatives. 
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CONCLUSION 
As a continuation of our scientific research based on the 
biologically active amidino substituted benazazoles, herein 
we present the design and synthesis of 2-phenyl 
substituted benzothiazole and benzimidazole derivatives 
bearing two types of amidino groups, either unsubstituted 
or cyclic amidine.  
 The mentioned compounds were synthesized to 
explore their antiproliferative activity in vitro on several 
cancer cells while results were compared to standard 
antiproliferative agent etoposide. 
 Additionally, our mail goal was also to study SAR and 
the influence of the type of substituent placed at the phenyl 
ring, the type of the benzazole nuclei as well as the type of 
the amidino group placed at the heteroaromatic nuclei on 
the antiproliferative activity. 
 The obtained results revealed that the majority  
of tested compounds showed moderate to high 
antiproliferative activity without significant selectivity 
between tested cell lines. The highest impact on the 
antiproliferative activity was shown by the type of the 
benzazole nuclei which led to the fact that all 
benzothiazole derivatives 3-5 and 7-10, with the 
exception of dihydroxy substituted derivative 6, showed 
improvement of antiproliferative activity in comparison 
to their benzimidazole analogues.  
 Additionally, the type of the attached amidino group 
on benzazole nuclei and substituents on the phehyl ring did 
not have the significant impact on the antiproliferative 
activity of tested benzothiazole derivatives with the 
exception of dihydroxy substituted derivatives 6 and 10. 
Oppositely, among the benzimidazole derivatives, 2-
imidazolinyl substituted derivatives 16-18 showed slightly 
enhancement of antiproliferative effect in comparison to 
amidino substituted analogues 12-14 with the exception of 
dihydroxy derivatives 15 and 19.  
 All obtained results revealed that this type of 
synthesized benzazoles, especially benzothiazole deriv-
atives, has a high potential for further optimization and 
improvement of their antiproliferative activity and 
selectivity against chosen cancer cell. 
Table 1. IC50(a) values of 2-phenylbenzothiazoles 3–10 and 2-phenylbezimidazoles 12–19. 
 
 
Cpd R1 R2 X Am 
Cell lines 
HCT116 MCF-7 H 460 
3 H CN S unsubstituted 2.4 ± 0.08 1.9 ± 0.4 1.9 ± 0.03 
4 H Cl S unsubstituted 2.5 ± 0.8 1.7 ± 0.26 1.5 ± 0.2 
5 H CF3 S unsubstituted 2.7 ± 1.9 1.7 ± 0.3 1.5 ± 0.3 
6 OH OH S unsubstituted > 100 > 100 > 100 
7 H CN S 2-imidazolinyl 2.6 ± 0.6 1.7 ± 0.4 2.8 ± 0.9 
8 H Cl S 2-imidazolinyl 2.5 ± 1.2 1.6 ± 0.4 1.25 ± 0.07 
9 H CF3 S 2-imidazolinyl 1.6 ± 0.5 1.6 ± 0.5 1.5 ± 0.2 
10 OH OH S 2-imidazolinyl 27 ± 12 21 ± 4 5 ± 1.4 
12 H CN NH unsubstituted > 100 55 ± 12 > 100 
13 H Cl NH unsubstituted 67 ± 2.5 12 ±0.4 81 ± 4 
14 H CF3 NH unsubstituted 65 ± 5 16 ± 1.3 > 100 
15 OH OH NH unsubstituted > 100 44 ± 0.5 > 100 
16 H CN NH 2-imidazolinyl 65 ± 5 16 ± 1.3 > 100 
17 H Cl NH 2-imidazolinyl 7.5 ± 2.5 5 ± 1.7 14 ± 1.6 
18 H CF3 NH 2-imidazolinyl 9 ± 0.9 6 ± 2 15 ± 3 
19 OH OH NH 2-imidazolinyl > 100 42 ± 1.2 > 100 
Etoposide  5 ± 2 1 ± 0.7 0.1 ± 0.04    
(a) The concentration that causes 50 % growth inhibition. 
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